ArticleFrontiers in medicine2026
Case Report: Rapid progression to end-stage renal disease within 3 years in tuberous sclerosis complex challenging conventional risk stratification.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder, with renal involvement typically presenting as angiomyolipomas (AML) and cysts. The progression to end-stage renal disease (ESRD) occurs in about 3.1% of cases. Current guidelines use AML size (>3 cm) as the threshold for initiating mTOR inhibitors, with less focus on rapidly progressing disease. This report describes a 28-year-old female with TSC whose renal function rapidly progressed from advanced CKD (stage G4A3) to anuria and ESRD within 3 years. She presented with significant proteinuria (3+, 5.94 g/24 h) and hematuria (3+) during pregnancy, but imaging showed no large tumors. Due to financial constraints, treatment was interrupted. Over approximately 30 months, her bilateral kidneys were replaced by diffuse AML, resulting in renal failure. This case challenges the traditional view of slow kidney progression in TSC and underscores the importance of early detection of proteinuria and hematuria as key warning signs. We recommend a multidisciplinary team (MDT) approach for high-risk patients, such as women of childbearing age, with dynamic monitoring of renal function and early proactive treatment to delay ESRD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.